4-chloro-5-methyl-2-methylthiopyrrolo[2,3-d]pyrimidine | 64609-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 4-chloro-5-methyl-2-methylthiopyrrolo[2,3-d]pyrimidine
• 英文别名: 4-Chloro-5-methyl-2-(methylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine；4-chloro-5-methyl-2-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine
• CAS: 64609-32-1
• 化学式: C₈H₈ClN₃S
• 分子量: 213.691
• InChiKey: GJMHCKTYEIFVBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-chloro-2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythropentofuranose 、 4-chloro-5-methyl-2-methylthiopyrrolo[2,3-d]pyrimidine 在 sodium hydride 作用下， 以 正己烷 、 乙腈 为溶剂， 以6.1 g (72%)的产率得到4-chloro-5-methyl-2-methylthio-7-[α-D-erythro-pentofuranosyl]pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  EP691980

  摘要：

  公开号：

文献信息

• Antiviral oligonucleotides having a conserved G4 core sequence
  申请人：Hanecak C. Ronnie

  公开号：US20070015723A1

  公开（公告）日：2007-01-18

  Modified oligonucleotides having a conserved G 4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A 2 or to modulate the telomere length of a chromosome are provided. G 4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A 2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.

  提供具有保守的G4序列和足够数量的侧翼核苷酸的修饰寡核苷酸，可以显著抑制病毒或磷脂酶A2的活性或调节染色体端粒长度。还提供了G4四链体寡核苷酸结构。还提供了预防病毒相关疾病和与磷脂酶A2水平升高相关的疾病的诊断和治疗方法。还提供了调节染色体端粒长度的方法；调节染色体端粒长度被认为在细胞老化过程和恶性细胞生长的控制中起作用。
• Antiviral Oligonucleotides Having a Conserved G4 Core Sequence
  申请人：Hanecak Ronnie C.

  公开号：US20110124715A1

  公开（公告）日：2011-05-26

  Modified oligonucleotides having a conserved G 4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus are provided. G 4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases are also provided.

  提供了具有保守的G4序列和足够数量的侧翼核苷酸以显著抑制病毒活性的修饰寡核苷酸。还提供了G4四联体寡核苷酸结构。此外，还提供了针对病毒相关疾病的预防、诊断和治疗方法。
• Oligonucleotides having a conserved G4 core sequence
  申请人：Isis Pharmaceuticals, Inc.

  公开号：US05952490A1

  公开（公告）日：1999-09-14

  Modified oligonucleotides having a conserved G.sub.4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A.sub.2 or to modulate the telomere length of a chromosome are provided. G.sub.4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnosis and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A.sub.2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to plat a role in the aging process of a cell and in control of malignant cell growth.

  提供了具有保守的G.sub.4序列和足够数量的侧翼核苷酸的修饰寡核苷酸，能够显著抑制病毒（如HSV-1或磷脂酶A.sub.2）的活性或调节染色体端粒长度。同时提供了G.sub.4四联体寡核苷酸结构。还提供了预防、诊断和治疗病毒相关疾病和与磷脂酶A.sub.2水平升高有关的疾病的方法。还提供了调节染色体端粒长度的方法；调节染色体端粒长度被认为在细胞衰老过程和恶性细胞生长的控制中扮演重要角色。
• NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3486244A1

  公开（公告）日：2019-05-22

  The present invention relates to a new compound having an FGFR inhibitory activity and preparation and application thereof. In particular, the compound according to the present invention has a structure as shown in formula I, wherein each group and substituent are as defined in the description. Also disclosed in the present invention are a preparation method for the compound and a use thereof in preparation of a drug for treating and/or preventing a tumor-related disease and/or an FGFR-related disease.

  本发明涉及一种具有 FGFR 抑制活性的新化合物及其制备和应用。特别是，根据本发明的化合物具有如式 I 所示的结构，其中各基团和取代基如描述中所定义。本发明还公开了该化合物的制备方法及其在制备治疗和/或预防肿瘤相关疾病和/或FGFR相关疾病的药物中的用途。
• [EN] NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF<br/>[FR] NOUVEAU COMPOSÉ PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DU FGFR, PRÉPARATION ET APPLICATION CORRESPONDANTES<br/>[ZH] 一种具有FGFR抑制活性的新型化合物及其制备和应用
  申请人：SHANGHAI INST MATERIA MEDICA CAS

  公开号：WO2017215485A1

  公开（公告）日：2017-12-21

  本发明涉及一种具有FGFR抑制活性的新型化合物及其制备和应用。具体地，本发明所述化合物具有式I所示结构，其中各基团和取代基如说明书中所定义。本发明还公开了所述化合物的制备方法及其在制备治疗和/或预防肿瘤相关疾病和/或FGFR相关疾病的药物中的用途。